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Urinary tract infections revisited
G Godaly1 and C Svanborg1
Urinary tract infections (UTIs) remain a significant clinical problem, 
despite antibiotic treatment and surgical correction of reflux and 
malformations. Here we propose that novel molecular tools may be 
applied to modernize and individualize the diagnosis and therapy 
of UTI. Determinants of bacterial virulence and host resistance are 
relatively well understood at the molecular level, and technology for 
their detection is within reach. 
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Two interesting papers on urinary tract 
infection (UTI) are published in this issue 
of Kidney International.1,2 Th ey raise the 
question of why UTIs continue to chal-
lenge and fascinate. UTIs are still among 
the most common bacterial infections in 
humans. Antibiotic treatment and other 
therapeutic interventions have been 
extremely important and successful, but 
despite modern therapy, the number of 
patients with recurrent infections remains 
high, and severe sequelae like renal dam-
age have not been eradicated. Further-
more, resistance to common antibiotics 
develops at a phenomenal pace, making 
it more important than ever to improve 
diagnostics and to identify alternative 
therapeutic approaches. Th e past decades 
have seen the success of molecular UTI 
research, and as a result, determinants of 
bacterial virulence and host resistance 
are much better understood than when 
antibiotics were introduced. Th e molecu-
lar information has not yet become inte-
grated into clinical practice, however. 
UTIs are often handled quite casually, 
and the patients who need special atten-
tion or referral to specialist clinics are 
oft en missed. Th ere is therefore a great, 
unmet need for tools that help optimize 
risk assessment and therapy in individual 
patients. One approach is to identify the 
‘bad bugs’ and ‘susceptible persons,’ recog-
nizing that most of the latter are female.
Th e severity of UTI is determined, to a 
large extent, by the virulence of the infect-
ing strain. Acute pyelonephritis is the most 
severe form of UTI and is oft en caused by 
uro-pathogenic Escherichia coli (UPEC), 
which are a distinct subset of the E. coli 
fl ora. In early studies, UPEC were distin-
guished from other E. coli strains by sero-
type,3 and more recently, in-depth analysis 
of their relatedness has been achieved by 
sequence analysis and array technology 
(reviewed by Johnson4 and by Hacker and 
Kaper5). Mechanistic studies of pathogen-
esis were initiated in the 1970s, when high 
tissue attachment was shown to character-
ize the most virulent strains.6,7 Th e link 
between attachment and virulence was 
gradually elucidated when attachment was 
identifi ed as a mechanism initiating tissue 
attack by the bacteria and as a trigger of 
the innate immune response of the host, 
leading to infl ammation and symptoms.8 
The molecular basis of virulence has 
since then been extensively studied, and a 
number of essential virulence factors have 
been identifi ed.6,7,9 Th e virulence genes 
are encoded on pathogenicity islands, and 
their expression, regulation, and evolution 
are the focus of ongoing studies.
Attachment is mediated by bacterial sur-
face fi mbriae, which bind to specifi c recep-
tors in the host mucosa and trigger the 
innate host response through co-receptors 
including the Toll-like receptors (TLRs) 
(Figure 1). P fi mbriae have been shown 
to fulfi ll all molecular Koch’s postulates as 
virulence factors in the urinary tract.7,10 
Th e most virulent UPEC strains express 
class II P fi mbriae,11 recognizing Galα1→
4Galβ receptor epitopes in the globoseries 
of glycosphingolipids, which are abundant 
in the uro-epithelium and in renal tissue.12 
Type 1 fi mbriae, in contrast, are expressed 
both by UPEC strains and by non-infecting 
commensals but have still been proposed 
to play a critical role for the persistence of 
E. coli in the murine urinary tract.13–16 
Type 1 fi mbriae recognize N-linked man-
nose residues in a wide range of glyco-
proteins, including the Tamm-Horsfall 
glycoprotein in the urine and the cell-
bound uroplakin Ia, which is expressed in 
the bladder but not in the renal pelvis.17–19 
P fi mbriae enhance bacterial persistence 
and infl ammation in the human urinary 
tract, but type 1 fi mbriae have not shown 
this eff ect.10,20
Th e new fi ndings presented by Tseng 
et al.2 and Godaly et al.1 expand our 
understanding of attachment and dis-
ease pathogenesis, especially the link to 
infl ammation. Tseng et al.2 demonstrate 
that the P fi mbrial adhesin papG is impor-
tant for the initial colonization of the host 
mucosa by virulent UPEC strains. Th ey 
selected a pyelonephritis strain, possess-
ing the class II P fi mbriae and type 1 fi m-
briae, but lacking other virulence factors, 
such as S/F1C-fi mbriae, hemolysin, and 
cytotoxic necrotizing factor 1. A papG 
II-defi cient mutant was constructed and 
compared with the wild-type strain in the 
murine model of Hagberg et al.21 Inter-
estingly, both strains behaved in a similar 
way, except for a diff erence in the early 
establishment of infection, during which 
the fully P fi mbriated UPEC strain colo-
nized signifi cantly more effi  ciently than 
the mutant strain. The results confirm 
early studies, which identifi ed P fi mbriae 
as virulence factors in mice (reviewed by 
Svanborg et al.7), but the eff ect of PapG II 
in the mouse model was smaller than pre-
viously reported. Th is may refl ect the fact 
that the strain also expressed type 1 fi m-
briae, which may substitute for P fi mbriae 
in the mouse model, when P fi mbriae are 
dysfunctional. Recently, Holden et al.22 
proposed that P fi mbriae repress type 1 
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fi mbrial expression. Th is is consistent with 
the results of Godaly et al.,1 as the chem-
okine response to the wild-type pyelone-
phritis isolate resembled the P fi mbriated 
recombinant strain.
Recent information has shed light on 
how fi mbrial adhesins may infl uence the 
epithelial cytokine responses, by activat-
ing diff erent transmembrane signaling 
pathways.23 Aft er binding to glycosphin-
golipid receptors, P fimbriated E. coli 
recruit TLR4 for transmembrane signal-
ing, independently of lipopolysaccharide 
and CD14.24,25 Studies in the murine UTI 
model have shown that the P fi mbriae use 
the TLR4 adaptor molecules Trif and Tram 
for signal transduction, rather than the 
lipopolysaccharide-related adaptor mol-
ecules MyD88 and TIRAP.23 Ceramide 
has been proposed as a signaling inter-
mediate, as ceramide is a TLR4 agonist 
and the membrane-anchoring domain of 
the glycolipid receptors is released aft er 
attachment.23,24 Th e response to type 1 
fi mbriated strains is also TLR4 depend-
ent but involves both lipopolysaccharide 
and the MyD88 adaptor.26,27 It may be 
speculated that the adaptor protein usage 
contributes to the diff erences in chemok-
ine repertoire observed in this study by 
Godaly et al., for example by diff erential 
regulation of transcription factors, but 
this needs further study. Th e results are 
consistent with the notion that fi mbriae 
infl uence signal transduction pathways 
and diff erentially regulate the transcrip-
tion of chemokine genes.1
The urinary tract maintains sterility 
by activating a multitude of lethal host 
defenses. Epithelial cells are early sensors 
of bacterial attack and secrete antibacte-
rial peptides, with a direct antibacterial 
eff ect.7,28,29 In addition, the chemokines 
rapidly recruit infl ammatory cells from 
the circulation to the mucosa, and neu-
trophils especially are important eff ector 
cells of the antibacterial defense.30,31 Th is 
process and the elimination of bacteria 
are controlled by chemokine receptor 
expression, and host resistance is directly 
modifi ed by individual CXCL8/CXCR1 
expression. In the murine UTI model, 
mIL-8Rh mutant mice have been shown 
to develop acute, bacteremic pyelone-
phritis and renal scarring, demonstrating 
that genetic factors can control UTI sus-
ceptibility.32 Furthermore, clinical stud-
ies have shown that pyelonephritis-prone 
patients and their relatives have reduced 
CXCR1 expression.32,33 Loss of TLR4 has 
the opposite eff ect, however. Tlr4-defi cient 
mice show an abrogated response to UTI, 
with little or no neutrophil recruitment, 
and are thus protected from acute infl am-
mation and tissue damage.34 In parallel, 
they develop asymptomatic bacteriuria, 
as the antibacterial defense also fails to be 
activated. Recent clinical studies have sug-
gested that children with primary asymp-
tomatic bacteriuria have reduced TLR4 
expression levels, suggesting that this 
mechanism might infl uence the outcome 
of human UTI, as well.35 Th ese fi ndings 
are directly relevant to the papers by Tseng 
et al.2 and Godaly et al.,1 as the host genet-
ics fi t as a mirror image to the mechanisms 
of fi mbria-mediated attachment, TLR4 
signaling, and chemokine activation.
So, do these studies provide any solu-
tions to the problems of ‘bad bugs’ and 
‘susceptible persons’? Is it possible to 
even discuss a more intellectual approach 
to the diagnosis and treatment of UTI, in 
an era when the value of urine cultures 
is being questioned? Do the complacency 
and lack of commitment in many clinics 
refl ect ignorance or the fact that UTI is 
a disease of children, of sometimes quite 
tiresome females, and of rather old men 
beyond their time of power? Clearly, mod-
ern tools make it possible to identify the 
‘bad bugs’ in urine cultures or by rapid, 
polymerase chain reaction-based tests. 
P fi mbriae (class II) are a prime candidate 
parameter, but several virulence factors 
may be included. Th e host response may 
be quantifi ed by established techniques 
for urine chemokine measurements, 
and genetic defects by immunological 
and molecular tools. If the symptomatic 
patient is infected by a virulent strain and 
shows a high chemokine response, treat-
ment and follow-up may be continued 
according to standard practice. Similarly, 
the fi nding of an avirulent strain and a low 
response in patients with asymptomatic 
bacteriuria may support a non-treatment 
decision. Th e patients who present with 
atypical clinical signs may be the ones with 
dysfunctional infl ammation and a poor 
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Figure 1 | Fully virulent uro-pathogenic Escherichia coli possess a wide arsenal of virulence 
factors and cause severe infections such as pyelonephritis and bacteremia. P fimbriated 
E. coli adhere to the Galα1®4Galβ receptor epitope in the globoseries of glycosphingolipids on 
the uro-epithelium and activate epithelial cells through Toll-like receptor 4 (TLR4) and the adaptor 
proteins TRIF and TRAM. Type 1 fimbriae recognize N-linked mannose residues in a wide range 
of glycoproteins. The response to type 1 fimbriated strains is also TLR4 dependent but involves 
lipopolysaccharide and the adaptor molecule MyD88. The different adaptor protein usage might 
thus contribute to the observed differences in chemokine repertoire.
Kidney International (2007) 71       723
commentar y
antibacterial defense, who are in need of 
investigation and possibly intervention by 
immunomodulation or prophylaxis.
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